Biosimilar Market- India
Base Year: 2023
Historical Years: 2018-2023
Forecast Years: 2024-2032
Market Growth Rate: 18.10% (2024-2032)
The India biosimilar market is rapidly growing, driven by increasing demand for affordable biologics, regulatory support, and technological advancements. According to the latest report by IMARC Group, the market is projected to grow at a CAGR of 18.10% from 2024 to 2032.
Download sample copy of the Report: https://www.imarcgroup.com/india-biosimilar-market/requestsample
India Biosimilar Market Trends and Drivers:
Rising Chronic Diseases: Increased prevalence of chronic conditions like cancer, diabetes, and autoimmune disorders requiring long-term biologic treatments.
Cost-Effectiveness: Biosimilars offer a more affordable alternative to original biologics, enhancing access to advanced therapies for a wider population.
Government Initiatives: Enhanced healthcare accessibility through government programs and integration of biosimilars into public healthcare systems.
Patent Expiration Opportunities: Expiration of patents for blockbuster biologics allows Indian pharmaceutical companies to develop and launch biosimilars domestically and internationally.
Advancements in R&D: Significant progress in biotechnological research leading to the production of high-quality, cost-effective biosimilars.
Strategic Partnerships: Indian pharmaceutical firms are forming collaborations with global players to strengthen their biosimilar portfolios and expand market reach.
Increasing Acceptance: Growing awareness and confidence in the safety and efficacy of biosimilars among healthcare professionals and patients.
Streamlined Regulations: Regulatory bodies in India are simplifying approval processes to encourage biosimilar development and commercialization.
Market Growth Potential: The rising demand for affordable biologic therapies positions the India biosimilar market for rapid expansion in the coming years, making it a key player in the global biosimilar landscape.
India Biosimilar Market Industry Segmentation:
The market report offers a comprehensive analysis of the segments, highlighting those with the largest India biosimilar market size. It includes forecasts for the period 2024-2032 and historical data from 2018-2023 for the following segments.
Breakup by Molecule:
- Infliximab
- Insulin Glargine
- Epoetin Alfa
- Etanercept
- Filgrastim
- Somatropin
- Rituximab
- Follitropin Alfa
- Adalimumab
- Pegfilgrastim
- Trastuzumab
- Bevacizumab
- Others
Breakup by Indication Insights:
- Auto-Immune Diseases
- Blood Disorder
- Diabetes
- Oncology
- Growth Deficiency
- Female Infertility
- Others
Breakup by Manufacturing Type:
- In-house Manufacturing
- Contract Manufacturing
Breakup by Region:
- North India
- West and Central India
- South India
- East and Northeast India
Competitive Landscape:
The report offers an in-depth examination of the competitive landscape. It includes a thorough competitive analysis encompassing market structure, key player positioning, leading strategies for success, a competitive dashboard, and a company evaluation quadrant.
Ask Analyst for Customization: https://www.imarcgroup.com/request?type=report&id=21512&flag=C
Key highlights of the Report:
- Market Performance (2018-2023)
- Market Outlook (2024-2032)
- COVID-19 Impact on the Market
- Porter’s Five Forces Analysis
- Strategic Recommendations
- Historical, Current and Future Market Trends
- Market Drivers and Success Factors
- SWOT Analysis
- Structure of the Market
- Value Chain Analysis
- Comprehensive Mapping of the Competitive Landscape
Note: If you need specific information that is not currently within the scope of the report, we can provide it to you as a part of the customization.
About Us:
IMARC Group is a global management consulting firm that helps the world’s most ambitious changemakers to create a lasting impact. The company provide a comprehensive suite of market entry and expansion services.
IMARC offerings include thorough market assessment, feasibility studies, company incorporation assistance, factory setup support, regulatory approvals and licensing navigation, branding, marketing and sales strategies, competitive landscape and benchmarking analyses, pricing and cost research, and procurement research.
Contact Us:
IMARC Group
134 N 4th St. Brooklyn, NY 11249, USA
Email: sales@imarcgroup.com
Tel No:(D) +91 120 433 0800
United States: +1-631-791-1145
